U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H16N2O
Molecular Weight 144.2147
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MILACEMIDE

SMILES

CCCCCNCC(N)=O

InChI

InChIKey=GJNNXIYZWIZFRH-UHFFFAOYSA-N
InChI=1S/C7H16N2O/c1-2-3-4-5-9-6-7(8)10/h9H,2-6H2,1H3,(H2,8,10)

HIDE SMILES / InChI

Molecular Formula C7H16N2O
Molecular Weight 144.2147
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Milacemide, a prodrug for glycine, is an inhibitor of the B form of monoamine oxidase. This drug could enhance dopaminergic activity in the brain and could be used as therapy for Parkinson's disease. Milacemide participated in clinical trials as a treatment for senile dementia of the Alzheimer type (SDAT). However, results have shown the drug was not an effective treatment in enhancing cognition in SDAT patients. In addition, milacemide has been tested for antiepileptic efficacy; however, this study was discontinued.

CNS Activity

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo
Route of Administration: Oral
Substance Class Chemical
Record UNII
0HXT24RECU
Record Status Validated (UNII)
Record Version